"But the Heart Doctor Said"…Optimizing Medication Management in Heart Failure Nearing Life's End
The past few years have been ripe with new treatment options for advanced heart failure with several of the agents providing incredible improvements in quality of life, functional status, hospitalization rate, and the risk of death. Despite this, use of guideline directed medical therapy during the course of illness and at the end-of-life for those with heart failure is suboptimal. This program will review the oldies, but goodies, and new agents on the market for management of heart failure and consideration for use of these agents at the end of life, debunking some of the myths that preclude use of guideline directed medical therapy. The presenter panel will address how to define “clinical success” when caring for a person with advanced heart failure and well as providing practical tips for use of drug therapy.
Hospice Medical Directors
Utilizing an interactive case-based approach, participants will self-report the ability to apply, analyze and evaluate:
- when/if chronic heart failure medications should be deprescribed based on the potential clinical benefit(s) of use.
- hemodynamic and/or side effects that should be taken into consideration when assessing the appropriateness guideline-directed medical therapies.
- attainable and realistic goals of care.
- a treatment and monitoring plan for symptom management.
AAHPM endorses the Accreditation Council for Continuing Medical Education (ACCME) Standards for disclosure and commercial support and endeavors to ensure balance, independence, objectivity, and scientific rigor for all accredited products or programs. All who are in a position to control or influence the content of an educational activity must disclose any relevant financial relationships with ineligible companies.*Disclosure documents were reviewed for potential conflicts of interest and, if identified, were resolved prior to confirmation of participation. Only those who had no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.
All editors, faculty and staff have disclosed no relevant financial relationships.
*An ineligible company is defined as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients.
Raya Kheirbek, MD MPH
Alexandra McPherson, PharmD MPH
Mary Lynn McPherson, PharmD MA MDE BCPS FAAHPM
Diana Violanti, PharmD BCPS
Kristin Watson, PharmD BCCP
Julie Tanner, BSN, RN-BC, CHPN
Julie Bruno, MSW, LCSW
Julie Tanner, BSN, RN-BC, CHPN
Continuing Medical Education (CME)
The American Academy of Hospice and Palliative Medicine (AAHPM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Hospice and Palliative Medicine (AAHPM) designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evaluation period closes May 31, 2022, for claiming CME credit.
Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Physicians certified with the American Board of Internal Medicine who wish to earn MOC points within the current calendar year must submit their MOC data no later than December 31 of the calendar year.
- 1.00 ABIM MOC
- 1.00 CME (physician only)
- 1.00 Participation